GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT01933334
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Chicago, Illinois, United States
A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01929876
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01911598
- Locations
- 🇺🇸
University of Chicago; Hematology/Oncology, Chicago, Illinois, United States
🇺🇸University of Colorado Cancer Center Department of Hematology, Aurora, Colorado, United States
🇧🇪Cliniques Universitaires St-Luc, Bruxelles, Belgium
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT01896531
- Locations
- 🇺🇸
Univ of Calif, Los Angeles; Hematology/Oncology, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States
🇮🇹Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica, Pisa, Toscana, Italy
A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT01877785
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01875705
- Locations
- 🇺🇸
Sarah Cannon Research Inst., Nashville, Tennessee, United States
🇫🇷Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France
🇺🇸Karmanos Can Inst, Detroit, Michigan, United States
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01868893
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Cancer Center of Central Conn., Southington, Connecticut, United States
🇺🇸Peachtree Hematology & Oncology Consultants, Pc, Atlanta, Georgia, United States
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
- Conditions
- Breast Cancer, Non-small Lung Cancer
- Interventions
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01862081
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Texas Oncology, P.A; Baylor Sammons Cancer Center, Dallas, Texas, United States
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT01846416
- Locations
- 🇺🇸
Ohio State Uni Hospital, Columbus, Ohio, United States
🇺🇸Penn Presbyterian Medical Center; Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT01823835
- Locations
- 🇳🇱
VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States